Piper Sandler analyst David Westenberg initiated coverage of 10x Genomics (TXG) with a Neutral rating and $15 price target The firm believes 10x has the best offering in single cell with the largest install base and a technological lead versus competitors. However, Piper recommends waiting for the company to navigate the current macro environment before buying the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10x Genomics and Cliseq Ltd. to investigate single cell applications
- CRSP, NTLA: Cathie Wood Adds to Biotech Favorites amid Buying Spree, Cuts Roku Stake
- Cathie Wood’s ARK Investment buys 105.1K shares of 10x Genomics today
- Cathie Wood Bets Millions on Biotech Stocks, Trims Roku and DraftKings
- Cathie Wood’s ARK Investment buys 215.3K shares of 10x Genomics today